You are here

Gossamer Bio

Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff

Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff

BioSpace

PTC Therapeutics

Urovant Sciences

Bristol Myers Squibb

ADC Therapeutics

Flag link:

Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs

Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs

Medical Marketing and Media

Bristol Myers Squibb

Flag link:

Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival

Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival

Fierce Biotech

Flag link:

Gossamer Bio announces FDA has placed a partial clinical hold on all trials of GB5121 in response to serious adverse events

Gossamer Bio announces FDA has placed a partial clinical hold on all trials of GB5121 in response to serious adverse events

Investing.com

Flag link:

Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile

Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile

Fierce Biotech

clinical trials

Flag link:

Gossamer could put pressure on Merck

Gossamer could put pressure on Merck

EP Vantage

United Therapeutics

Flag link:

Phase 2 deja vu for gossamer bio after ulcerative colitis med flops

Phase 2 deja vu for gossamer bio after ulcerative colitis med flops

Fierce Biotech

ulcerative colitis

clinical trials

Flag link:

Gossamer Bio seeking out partners for failed DP2 antagonist, says it has 'viable path forward'

Gossamer Bio seeking out partners for failed DP2 antagonist, says it has 'viable path forward'

Fierce Biotech

eosinophilic asthma

Flag link:

Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

Xconomy

clinical trials

eosinophilic asthma

Flag link:

Biotech companies raise cash as coronavirus updates lift stocks

Biotech companies raise cash as coronavirus updates lift stocks

BioPharma Dive

Moderna Therapeutics

Turning Point Therapeutics

Krystal Biotech

Clovis Oncology

Flag link:

A Look at 5 Big and Interesting Biotech IPOs for 2019

A Look at 5 Big and Interesting Biotech IPOs for 2019

BioSpace

Adaptive Biotechnologies

Flag link:

Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects

Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects

Fierce Biotech

clinical trials

Flag link:

BioSpace's List of February 2019 Life Science IPOs

BioSpace's List of February 2019 Life Science IPOs

BioSpace

Shockwave Medical

Harpoon Therapeutics

Hoth Therapeutics

Flag link:

Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019

Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019

Xconomy

Flag link:

With US government shutdown over, Gossamer reverts to traditional IPO plan

With US government shutdown over, Gossamer reverts to traditional IPO plan

Endpoints

government shutdown

Flag link:

Gosssamer Bio to Use 20 Day Rule for $230 Million IPO

Flag link:

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

BioCentury

government shutdown

Flag link:

Gossamer Bio Plans to Raise $264.5 Million with IPO

Gossamer Bio Plans to Raise $264.5 Million with IPO

BioSpace

Flag link:

Four Healthcare Startups Raised Over $130 Million Last Month

Four Healthcare Startups Raised Over $130 Million Last Month

Forbes

Compass Therapeutics

Flag link: